A systematic review of taxane-containing regimens for metastatic breast cancer.
about
A new extract of the plant Calendula officinalis produces a dual in vitro effect: cytotoxic anti-tumor activity and lymphocyte activationMeta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancerPhase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experienceRandomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden.Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer.Expression and silencing of the microtubule-associated protein Tau in breast cancer cells.Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy?International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells.Taxanes for the treatment of metastatic breast cancer.Second-line treatment of postmenopausal women with advanced breast carcinoma.Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199.Progression-free survival as a surrogate endpoint in advanced breast cancerCapecitabine-docetaxel combination treatment.Use of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer.Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197Blood flow and glucose metabolism in stage IV breast cancer: heterogeneity of response during chemotherapy.Genetic inactivation and pharmacological blockade of sigma-1 receptors prevent paclitaxel-induced sensory-nerve mitochondrial abnormalities and neuropathic pain in mice.Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African Americans.Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.The microtubule as a breast cancer target.Recent developments in treatment stratification for metastatic breast cancer.Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review.Taxane benefit in breast cancer--a role for grade and chromosomal stability.A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer.Caveolin-1 tyrosine phosphorylation enhances paclitaxel-mediated cytotoxicity.Docetaxel rechallenge after a first response in non-resistant metastatic breast cancer: significant activity with manageable toxicity.Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802).Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer.The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition.The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer.Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience.
P2860
Q21260433-4BE7AECE-FE87-4D24-970A-79A17C756A04Q26860469-097F6941-54C1-478E-BB38-4B1C46CE059AQ33237182-4817D49E-83D6-47AF-A49C-FC9738843984Q33738990-D86E0B3A-B9AB-436C-BC97-706B9FFA2C7EQ33913545-66AC98C0-0891-4A0A-9C49-A5BDBF829C08Q34026054-8757C0D5-7FF4-4D5E-BE16-67E61AA2C95BQ34726680-D7ABD285-01EF-4E7E-B587-63B1AF8743E5Q35815486-A68DD16B-D56C-4CEC-BA64-46A963E68773Q35820247-6AEB9DB9-FE64-4487-A863-4B13FA0B038BQ36045385-BC0A0BFC-494F-46B2-93B8-EFC0C1C22B54Q36364762-13F4D638-48FD-4745-BC10-E1CBCCFC4DE9Q36448699-103675CF-598A-4AF3-B61B-74C14069A6F6Q36475847-495E296A-1EB3-4DC5-89DD-070348231B54Q36552307-BB807B31-95EB-4815-B352-91BA82535DBBQ36613965-238BE442-5341-48C5-89C1-073BEA637752Q36627745-7678B063-6792-41D1-B51C-D2EE70555AFFQ37125089-7949D48F-ABA8-402B-BDC1-0CFC23F41AF1Q37228097-8A0807F4-4042-4855-BD44-866DD05F475BQ37583394-67B8CFCC-3CB1-4993-B2CC-6E436BBAC1B0Q37696110-C7C2E398-3DE5-4318-8844-CE732CFC6BA2Q37718401-90A8E974-886B-4A46-BA4F-DE30F2BEBBE7Q37791482-1C3260EC-31B5-4DC4-965D-B549E2BAFC0BQ37950515-376DDB4B-48D3-4B20-B201-EFAB9656B476Q37960507-CD879204-1B7F-4EF3-99C0-B80F9E707E5EQ38104568-D7F6C45E-8802-4E60-961F-54285E7CB1E3Q39766776-125B6E3C-B84A-4260-9599-AD5ECDEEEB5DQ40190072-D20B2DA1-AA5E-4F52-B5B4-B78BA5327BF8Q44915628-824941E6-9F23-45FA-8C59-FE05C779B84DQ46103036-A6511E9B-D4B0-4819-A559-20EC2CA61409Q47967056-C034BD38-CA16-46FF-9F8D-1F9D3EF059F4Q54212765-21AC6CF7-A9EB-4E20-9A19-F2F5F9697EDCQ54324247-26A4C359-483E-4FAF-BD7A-714AF45A7300Q54459895-5F2375EC-888A-46EF-A755-D6D96562FD53
P2860
A systematic review of taxane-containing regimens for metastatic breast cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
A systematic review of taxane-containing regimens for metastatic breast cancer.
@ast
A systematic review of taxane-containing regimens for metastatic breast cancer.
@en
type
label
A systematic review of taxane-containing regimens for metastatic breast cancer.
@ast
A systematic review of taxane-containing regimens for metastatic breast cancer.
@en
prefLabel
A systematic review of taxane-containing regimens for metastatic breast cancer.
@ast
A systematic review of taxane-containing regimens for metastatic breast cancer.
@en
P2093
P2860
P31
P921
P356
P1476
A systematic review of taxane-containing regimens for metastatic breast cancer.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602680
P407
P577
2005-08-01T00:00:00Z
2005-08-08T00:00:00Z